- Conditions
- Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia
- Interventions
- HTX-011, Bupivacaine Hydrochloride, MMA regimen, ZYNRELEF kit components for administration
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Jenks, Oklahoma • Bellaire, Texas + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postoperative Pain
- Interventions
- HTX-011, ZYNRELEF kit components for administration, MMA regimen
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Sheffield, Alabama • San Diego, California • Durham, North Carolina + 1 more
- Conditions
- Periarticular Block, Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Pain After Surgery, Knee Arthroplasty, Total
- Interventions
- bupivacaine-meloxicam (extended release), Bupivacaine, Ketorolac, Lidocaine (drug)
- Combination Product · Drug
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cranberry Township, Pennsylvania
- Conditions
- Knee Osteoarthritis, Arthritis Knee
- Interventions
- ZYNRELEF 400Mg-12Mg Extended-Release Solution, Ultrasound-Guided Adductor Canal Block, Ropivacaine 0.5% Injectable Solution
- Drug · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Osteoarthritis (OA) of the Knee
- Interventions
- Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Grosse Pointe Farms, Michigan
- Conditions
- Postoperative Pain, Abdominoplasty Surgery, Multimodal Analgesia
- Interventions
- MMA regimen, ZYNRELEF kit components for administration, HTX-011, Bupivacaine Hydrochloride
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • San Antonio, Texas
- Conditions
- Readiness to Discharge
- Interventions
- Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
- Procedure
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pain, Postoperative
- Interventions
- Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement
- Drug · Procedure
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Post Operative Pain, Osteoarthritis, Knee
- Interventions
- Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Total Knee Arthroplasty
- Interventions
- HTX-011, ropivacaine , epinephrine , ketorolac diluted in sodium chloride
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
- Interventions
- ZYNRELEF 200Mg-6Mg Extended-Release Solution
- Drug
- Lead sponsor
- Dr. Yannis Raftopoulos
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Holyoke, Massachusetts